undamentalytics Newsletter
Sign in

Innoviva, Inc. balance sheet

At the end of fiscal 2025, Innoviva, Inc. had total assets of $1.64bn and shareholders' equity of $1.17bn. It held $551m in cash against $261m of debt: net cash of $290m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents481634595144971591187362278246202291194305551570
Receivables———000————————————
Inventory———8100——————05641343939
Total current assets—316245261483252214198200199431342314444344554728753
Goodwill————————————02718181818
Total assets—3312593696815224093793675487251,0009261,2311,2441,3011,6351,703
Accounts payable—26580101000037254
Deferred revenue (current)—2219591110———021146
Total current liabilities—40453084141320356566135382365047
Short-term debt—00———08————09601920—
Long-term debt—0——288726733708574383377386395444446256258258
Total debt0000288726748728574383377433433550454454261261
Shareholders' equity−189−22−87155299−223−343−353−2431543135404155666756911,1731,233
Net debt (negative = net cash)−48−163−45−9514462958961050132099187232259260149−290−309
Shares outstanding——86m98m112m————101m101m101m———63m75m73m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: INVA vs IRWDINVA vs XERSALVO vs INVA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Innoviva, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Innoviva, Inc.